We are joined by Rakesh Popat, from University College London Hospitals NHS Foundation Trust, at the EHA annual meeting in 2019 to discuss his presentation on the pursuit of antigen targets for relapsed/refractory multiple myeloma.
1. What are the current treatment options for relapsed/refractory multiple myeloma (MM) and what are their limitations? (0:05)
2. What is the rationale for targeting B-cell maturation antigen in relapsed/refractory MM? (1:20)
3. Could you tell us a little about the structure and mechanism of action of GSK2857916? (2:30)
4. Could you tell us about your phase I study investigating GSK2857916 and its findings? (3:22)
5. What were the findings of the study investigating patient-reported outcomes with GSK2857916? (4:40)
Dr Rakesh Popat has provided consultancy for GlaxoSmithKline Pharmaceuticals Ltd.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Multiple Myeloma
Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma
Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene […]
Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma
The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases. The abstract entitled ‘First phase 3 results from CARTITUDE-4: Cilta-cel versus […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!